Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...

With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...

The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

Of the interviewed providers, 53.4% had experience with food allergy clinical trials, and 85% offered oral immunotherapy to ...

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.